Page 1

nurix Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update October 14 , 2021 Initiated Phase 1 trial of lead CBL - B E3 ligase inhibitor program NX - 1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $ 465.4 million as of August 31 , 2021 SAN FRANCISCO , Oct. 14 , 2021 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics , Inc. ( Nasdaq : NRIX ) , a biopharmaceutical company developing targeted protein modulation drugs , today reported financial results for the third quarter ended August 31 , 2021 and provided a corporate update . " With the recent initiation of a Phase 1 trial for our lead E3 ligase inhibitor program NX - 1607 , we now have two wholly owned drug candidates in clinical development , both potentially addressing significant unmet needs in hematology and oncology , " said Arthur T. Sands , M.D. , Ph.D. , president and chief executive officer of Nurix . " The remainder of 2021 promises to be an exciting time for Nurix as we prepare to deliver on our ambitious goal of initiating Phase 1 trials for two additional wholly owned and internally developed drug candidates . " Recent Business Highlights • Advanced NX - 1607 into Phase 1 Clinical Development : Nurix initiated its Phase 1a / 1b study to evaluate orally dosed small molecule NX - 1607 , a Casitas B - lineage lymphoma proto - oncogene ( CBL - B ) inhibitor at clinical sites in the United Kingdom . The multicenter , open - label Phase 1 dose escalation and expansion trial will evaluate the safety and tolerability of NX - 1607 in adults with a variety of oncology indications . • Expanded the Board of Directors with Experienced Business Leaders : Nurix announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors , effective October 1 , 2021. Ms. Reinsdorf is the former executive vice president and general counsel of Johnson Controls International , and Mr. Silva is the former senior vice president , chief accounting officer at Vertex Pharmaceuticals Incorporated . Nurix previously announced the appointment of Clay Siegall , Ph.D. , to its board , effective May 28 , 2021. Dr. Siegall is the co - founder of Seagen Inc. ( formerly Seattle Genetics , Inc. ) and serves as its president , chief executive officer and chairman of the board . Upcoming Program Highlights * • NX - 2127 : Nurix's lead drug candidate from its protein degradation portfolio , NX - 2127 , is an orally bioavailable degrader of BTK with immunomodulatory drug ( IMID ) activity for the treatment of relapsed or refractory B - cell malignancies . Nurix is conducting its Phase 1 clinical trial of NX - 2127 at multiple clinical sites . Initial pharmacokinetic ( PK ) and pharmacodynamic ( PD ) data from the dose escalation portion of the trial is anticipated by year - end 2021. Additional information on the clinical trial can be accessed at ClinicalTrials.gov ( NCT04830137 ) . • NX - 1607 : Nurix's lead drug candidate from its E3 ligase inhibitor portfolio , NX - 1607 , is an orally bioavailable inhibitor of CBL - B for immuno - oncology indications . Nurix recently initiated the dose escalation portion of its ongoing Phase 1 trial . • NX - 5948 : Nurix's second drug candidate from its protein degradation portfolio , NX - 5948 , is an orally bioavailable BTK degrader designed without IMID activity for certain B - cell malignancies and autoimmune diseases . Nurix anticipates initiating a Phase 1 trial for NX - 5948 in patients with hematologic malignancies in the second half of 2021 and is planning for the potential expansion of indications into selected autoimmune diseases in 2022 . • DeTIL - 0255 : Nurix's lead candidate in its cellular therapy portfolio , DeTIL - 0255 , is a drug - enhanced adoptive cellular therapy . Nurix anticipates initiating a Phase 1 trial for DeTIL - 0255 in the second half of 2021 . * Expected timing of events throughout the press release are based on calendar year quarters . Fiscal Third Quarter 2021 Financial Highlights Collaboration revenue for the three months ended August 31 , 2021 was $ 10.3 million compared to $ 4.1 million for the three months ended August